Berbamine suppresses intestinal SARS-CoV-2 infection via a BNIP3-dependent autophagy blockade

References

• Caniels TG, Bontjer I, van der Straten K, et al. Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccination. Sci Adv. 2021 Sep 3;7:eabj5365–eabj5365.
   PubMed Web of Science ®Google Scholar
• Iketani S, Liu L, Guo Y, et al. Antibody evasion properties of SARS-CoV-2 Omicron sublineages. Nature. 2022;604:553–556.
   PubMed Web of Science ®Google Scholar
• Jiang X-L, Zhu K-L, Wang X-J, et al. Omicron BQ.1 and BQ.1.1 escape neutralisation by omicron subvariant breakthrough infection. Lancet Infect Dis. 2023;23:28–30. Available from: https://www.sciencedirect.com/science/article/pii/S1473309922008052
   PubMedGoogle Scholar
• Zhang L, Li Q, Liang Z, et al. The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron. Emerg Microbes Infect. 2022;11:1–5. doi:10.1080/22221751.2021.2017757
   PubMed Web of Science ®Google Scholar
• World Health Organization. Statement on Omicron sublineage BA.2 [Internet]. 2022 [cited 2022 Nov 8]. Available from: https://www.who.int/news/item/22-02-2022-statement-on-omicron-sublineage-ba.2
   Google Scholar
• Willett BJ, Grove J, MacLean OA, et al. SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway. Nat Microbiol. 2022;7:1161–1179.
   PubMed Web of Science ®Google Scholar
• Tuekprakhon A, Nutalai R, Dijokaite-Guraliuc A, et al. Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. Cell. 2022;185:2422–2433.e13.
   PubMed Web of Science ®Google Scholar
• Davis-Gardner ME, Lai L, Wali B, et al. Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA bivalent booster. New England J Med. 2023;388:183–185. doi:10.1056/NEJMc2214293
   PubMed Web of Science ®Google Scholar
• Wu X, Jing H, Wang C, et al. Intestinal damage in COVID-19: SARS-CoV-2 infection and intestinal thrombosis. Front Microbiol. 2022;13:860931.
   PubMed Web of Science ®Google Scholar
• Meringer H, Mehandru S. Gastrointestinal post-acute COVID-19 syndrome. Nat Rev Gastroenterol Hepatol. 2022;19(6):345–346.
   PubMed Web of Science ®Google Scholar
• Natarajan A, Zlitni S, Brooks EF, et al. Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA suggest prolonged gastrointestinal infection. Med. 2022;3:371–387.e9.
   PubMedGoogle Scholar
• Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA. 2020;323:1843–1844.
   PubMed Web of Science ®Google Scholar
• Lehmann M, Allers K, Heldt C, et al. Human small intestinal infection by SARS-CoV-2 is characterized by a mucosal infiltration with activated CD8+ T cells. Mucosal Immunol. 2021;14:1381–1392.
   PubMed Web of Science ®Google Scholar
• Lamers MM, Beumer J, van der Vaart J, et al. SARS-CoV-2 productively infects human gut enterocytes. Science. 2020;369(6499):50–54.
   PubMed Web of Science ®Google Scholar
• Zhou J, Li C, Liu X, et al. Infection of bat and human intestinal organoids by SARS-CoV-2. Nat Med. 2020;26:1077–1083.
   PubMed Web of Science ®Google Scholar
• Kaufmann SHE, Dorhoi A, Hotchkiss RS, et al. Host-directed therapies for bacterial and viral infections. Nat Rev Drug Discov. 2018;17:35–56.
   PubMed Web of Science ®Google Scholar
• Cloherty APM, van Teijlingen NH, Eisden T-JTHD, et al. Autophagy-enhancing drugs limit mucosal HIV-1 acquisition and suppress viral replication ex vivo. Sci Rep. 2021;11:4767.
   PubMed Web of Science ®Google Scholar
• Shapira T, Monreal IA, Dion SP, et al. A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic. Nature. 2022;605:340–348.
   PubMed Web of Science ®Google Scholar
• Sargazi S, Sheervalilou R, Rokni M, et al. The role of autophagy in controlling SARS-CoV-2 infection: an overview on virophagy-mediated molecular drug targets. Cell Biol Int. 2021;45:1599–1612. doi:10.1002/cbin.11609
   PubMed Web of Science ®Google Scholar
• Haq S, Grondin J, Banskota S, et al. Autophagy: roles in intestinal mucosal homeostasis and inflammation. J Biomed Sci. 2019;26(19).
   PubMedGoogle Scholar
• Nighot PK, Hu C-AA, Ma TY. Autophagy enhances intestinal epithelial tight junction barrier function by targeting claudin-2 protein degradation. J Biol Chem. 2015;290:7234–7246.
   PubMed Web of Science ®Google Scholar
• Yang Y, Li W, Sun Y, et al. Amino acid deprivation disrupts barrier function and induces protective autophagy in intestinal porcine epithelial cells. Amino Acids. 2015;47:2177–2184.
   PubMed Web of Science ®Google Scholar
• Singh K, Chen YC, Hassanzadeh S, et al. Network analysis and transcriptome profiling identify autophagic and mitochondrial dysfunctions in SARS-CoV-2 infection. Front Genet. 2021;12:599261.
   PubMed Web of Science ®Google Scholar
• Gassen NC, Papies J, Bajaj T, et al. SARS-CoV-2-mediated dysregulation of metabolism and autophagy uncovers host-targeting antivirals. Nat Commun. 2021;12:3818.
   PubMed Web of Science ®Google Scholar
• Maity S, Saha A. Therapeutic potential of exploiting autophagy cascade against coronavirus infection. Front Microbiol Frontiers Media S.A. 2021;12:675419.
   PubMed Web of Science ®Google Scholar
• Koepke L, Hirschenberger M, Hayn M, et al. Manipulation of autophagy by SARS-CoV-2 proteins. Autophagy. 2021;17:2659–2661. doi:10.1080/15548627.2021.1953847
   PubMed Web of Science ®Google Scholar
• Reggiori F, Monastyrska I, Verheije MH, et al. Coronaviruses hijack the LC3-I-positive EDEMosomes, ER-derived vesicles exporting short-lived ERAD regulators, for replication. Cell Host Microbe. 2010;7:500–508.
   PubMed Web of Science ®Google Scholar
• Ghosh S, Dellibovi-Ragheb TA, Kerviel A, et al. β-Coronaviruses use lysosomes for egress instead of the biosynthetic secretory pathway. Cell. 2020;183:1520–1535.e14.
   PubMed Web of Science ®Google Scholar
• Zhao H, Lu L, Peng Z, et al. SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with Delta variant in TMPRSS2-expressed cells. Emerg Microbes Infect. 2022;11:277–283.
   PubMed Web of Science ®Google Scholar
• Aggarwal A, Akerman A, Milogiannakis V, et al. SARS-CoV-2 Omicron BA.5: evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern. EBioMedicine. 2022;84:104270.
   Web of Science ®Google Scholar
• Mou L, Liang B, Liu G, et al. Berbamine exerts anticancer effects on human colon cancer cells via induction of autophagy and apoptosis, inhibition of cell migration and MEK/ERK signalling pathway. JBUON. 2019;24(5):1870–1875.
   Google Scholar
• Nevitt SJ, Sudell M, Weston J, et al. Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data. Cochrane Database Syst Rev. 2017;12:CD011412–CD011412.
   PubMedGoogle Scholar
• Yang M-T, Lin Y-C, Ho W-H, et al. Everolimus is better than rapamycin in attenuating neuroinflammation in kainic acid-induced seizures. J Neuroinflammation. 2017;14:15.
   PubMed Web of Science ®Google Scholar
• Ribeiro CMS, Sarrami-Forooshani R, Setiawan LC, et al. Receptor usage dictates HIV-1 restriction by human TRIM5α in dendritic cell subsets. Nature. 2016;540:448–452.
   PubMed Web of Science ®Google Scholar
• Birgisdottir ÅB, Johansen T. Autophagy and endocytosis – interconnections and interdependencies. J Cell Sci. 2020;133:jcs228114.
   PubMed Web of Science ®Google Scholar
• Roodsant T, Navis M, Aknouch I, et al. A human 2D primary organoid-derived epithelial monolayer model to study host-pathogen interaction in the small intestine. Front Cell Infect Microbiol. 2020;10.
   PubMed Web of Science ®Google Scholar
• Srinivasan B, Reddy Kolli A. Teer measurement techniques for in vitro barrier model systems. J Lab Autom. 2020;10:272.
   Google Scholar
• Bjorndal A, Deng H, Jansson M, et al. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J Virol. 1997;71:7478–7487.
   PubMed Web of Science ®Google Scholar
• N’Diaye E-N, Kajihara KK, Hsieh I, et al. Plic proteins or ubiquilins regulate autophagy-dependent cell survival during nutrient starvation. EMBO Rep. 2009;10:173–179.
   PubMed Web of Science ®Google Scholar
• Gump JM, Thorburn A. Sorting cells for basal and induced autophagic flux by quantitative ratiometric flow cytometry. Autophagy. 2014;10:1327–1334.
   PubMed Web of Science ®Google Scholar
• Klionsky DJ, Abdel-Aziz AK, Abdelfatah S, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition). Autophagy. 2021;17:1–382.
   PubMed Web of Science ®Google Scholar
• Crawford KHD, Eguia R, Dingens AS, et al. Protocol and reagents for pseudotyping lentiviral particles with SARS-CoV-2 spike protein for neutralization assays. Viruses. 2020;12(5):513.
   PubMed Web of Science ®Google Scholar
• Bermejo-Jambrina M, Eder J, Kaptein TM, et al. Infection and transmission of SARS-CoV-2 depend on heparan sulfate proteoglycans. EMBO J. 2021;40(20):e106765.
   PubMed Web of Science ®Google Scholar
• Shapira T, Rankine-Wilson L, Chao JD, et al. High-content screening of eukaryotic kinase inhibitors identify CHK2 inhibitor activity against mycobacterium tuberculosis. Front Microbio. 2020;11:553962.
   PubMedGoogle Scholar
• Olmstead AD, Knecht W, Lazarov I, et al. Human subtilase SKI-1/S1P is a master regulator of the HCV lifecycle and a potential host cell target for developing indirect-acting antiviral agents.. PLoS Pathog. 2012;8:e1002468.
   PubMed Web of Science ®Google Scholar
• Sridhar A, Simmini S, Ribeiro CMS, et al. A perspective on organoids for virology research. Viruses. 2020;12:1341.
   PubMed Web of Science ®Google Scholar
• Fu R, Deng Q, Zhang H, et al. A novel autophagy inhibitor berbamine blocks SNARE-mediated autophagosome-lysosome fusion through upregulation of BNIP3. Cell Death Dis. 2018;9:243.
   PubMed Web of Science ®Google Scholar
• Wu M, Wang S, Cai C, et al. Natural autophagy blockers, dauricine (DAC) and daurisoline (DAS), sensitize cancer cells to camptothecin-induced toxicity. Oncotarget. 2017;8:77673–77684.
   Google Scholar
• Nowak E, Kammerer S, Küpper J-H. ATP-based cell viability assay is superior to trypan blue exclusion and XTT assay in measuring cytotoxicity of anticancer drugs taxol and imatinib, and proteasome inhibitor MG-132 on human hepatoma cell line HepG2. Clin Hemorheol Microcirc. 2018;69:327–336.
   PubMed Web of Science ®Google Scholar
• Kaur J, Debnath J. Autophagy at the crossroads of catabolism and anabolism. Nat Rev Mol Cell Biol. 2015;16:461–472. doi:10.1038/nrm4024
   PubMed Web of Science ®Google Scholar
• Habtemariam S. Berberine and inflammatory bowel disease: a concise review. Pharmacol Res. 2016;113:592–599.
   PubMed Web of Science ®Google Scholar
• Jia X-J, Li X, Wang F, et al. Berbamine exerts anti-inflammatory effects via inhibition of NF-κB and MAPK signaling pathways. Cell Physiol Biochem. 2017;41:2307–2318.
   PubMedGoogle Scholar
• Ma X, Godar RJ, Liu H, et al. Enhancing lysosome biogenesis attenuates BNIP3-induced cardiomyocyte death. Autophagy. 2012;8:297–309.
   PubMed Web of Science ®Google Scholar
• Bojkova D, Widera M, Ciesek S, et al. Reduced interferon antagonism but similar drug sensitivity in Omicron variant compared to Delta variant of SARS-CoV-2 isolates. Cell Res. 2022;32:319–321.
   PubMed Web of Science ®Google Scholar
• de Oliveira AP, Lopes ALF, Pacheco G, et al. Premises among SARS-CoV-2, dysbiosis and diarrhea: walking through the ACE2/mTOR/autophagy route. Med Hypotheses. 2020;144:110243. Available from: https://www.sciencedirect.com/science/article/pii/S0306987720311518
   PubMed Web of Science ®Google Scholar
• Huang L, Yuen TT-T, Ye Z, et al. Berbamine inhibits SARS-CoV-2 infection by compromising TRPMLs-mediated endolysosomal trafficking of ACE2. Signal Transduct Target Ther. 2021;6:168.
   PubMed Web of Science ®Google Scholar
• Zhang Z-R, Zhang Y-N, Zhang H-Q, et al. Berbamine hydrochloride potently inhibits SARS-CoV-2 infection by blocking S protein-mediated membrane fusion. PLoS Negl Trop Dis. 2022;16:e0010363. doi:10.1371/journal.pntd.0010363.
   PubMed Web of Science ®Google Scholar
• Miller J, Hachmann NP, Collier AY, et al. Substantial neutralization escape by SARS-CoV-2 Omicron variants BQ.1.1 and XBB.1. New England J Med. 2023. doi:10.1056/NEJMc2214314.
   Web of Science ®Google Scholar
• Qu P, Evans JP, Faraone JN, et al. Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2. Cell Host Microbe. 2023;31:9–17.e3. Available from: https://www.sciencedirect.com/science/article/pii/S1931312822005686
   PubMed Web of Science ®Google Scholar
• Khiali S, Khani E, Rouy S B, et al. Comprehensive review on molnupiravir in COVID-19: a novel promising antiviral to combat the pandemic. Future Microbiol. 2022;17(5):377–391.
   PubMed Web of Science ®Google Scholar